For the first time, 8 Lakhs new customers used Metropolis for COVID-19 tests. In H2FY21, we saw a healthy conversion rate of 10% of customers who tried Metropolis for a Non-COVID Test. We anticipate higher conversion rates in the coming quarters.
EBIDTA: Earnings Before Interest, Depreciation, Taxes and Amortisation |PAT: Profit after Tax |B2C: Business to Customers
Incepted in the year 1980, Metropolis is among is among the leading diagnostics players in India, with a dominant share in the country’s western and southern region. Metropolis offers a comprehensive range of 4,000+ clinical laboratory tests and profiles as one of the market leaders. These tests are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of different diseases. Additionally, the Company also offers analytical and support services to clinical research organisations for their clinical research projects. Growing strength by strength, the Company has spread its footprints across 19 Indian states and 210 cities.
All figures as on March 31, 2021
*CAP: College of American Pathologists *NABL: National Accreditation Board for Testing and Calibration Laboratories
To be a respected healthcare brand trusted by clinicians, patients and stakeholders. Positively impact lives of patients in their most anxious times and turn their anxiety in to assurance.
Helping people stay healthy, by accurately revealing their inner health.